Full Press Release Details
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials.
BIIB
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
Key Takeaway: FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis